泰格医药(03347.HK)参与投资博远二期人民币基金 认缴出资5,000万人币
泰格医药(03347.HK)公布,投资平台杭州泰格股权投资合伙企业拟以自有资金投资博远二期人民币基金(下称合伙企业)。合伙企业的目标认缴出资总额为15亿元至20亿元人民币(下同),公司将作为该合伙企业的有限合伙人认缴出资5,000万元。
合夥企业主要投资有增长潜力、优质的医疗健康产业相关企业或其他经济实体,包括但不限於运营医药、生物科技、医疗服务、医疗器械、设备、诊断,动物保健,及其他医疗健康相关领域的企业。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.